Statistical analysis of cost–effectiveness data from randomized clinical trials

References

• Willan AR, Lin DY, Cook RJ, Chen EB. Using inverse-weighing in cost–effectiveness analysis with censored data. Stat. Methods Med. Res.11, 539–551 (2002).
   PubMed Web of Science ®Google Scholar
• Willke RJ, Glick HA, Polsky D, Schulman K. Estimating country-specific cost–effectiveness from multinational clinical trials. Health Econ.7, 481–493 (1998).
   PubMed Web of Science ®Google Scholar
• Cook JR, Drummond M, Glick H, Heyse JF. Assessing the appropriateness of combining economic data from multinational clinical trials. Stat. Med.22, 1955–1976 (2003).
   PubMed Web of Science ®Google Scholar
• Grieve R, Nixon R, Thompson SG, Normand C. Using multilevel models for assessing the variability of multinational resource use and cost data. Health Econ.14, 185–196 (2005).
   PubMed Web of Science ®Google Scholar
• Willan AR, Pinto EM, O’Brien BJ et al. Country-specific cost comparisons from multinational clinical trials using empirical Bayesian shrinkage estimation: The Canadian ASSENT-3 Economic Analysis. Health Econ.14, 327–338 (2005).
   PubMed Web of Science ®Google Scholar
• Manca A, Rice N, Sculpher MJ, Briggs AH. Assessing generalisability by location in trial-based cost–effectiveness analysis: the use of multilevel models. Health Econ.14, 471–475 (2005).
   PubMed Web of Science ®Google Scholar
• Pinto EM, Willan AR, O’Brien BJ. Cost–effectiveness analysis for multinational clinical trials. Stat. Med.24, 1965–1982 (2005).
   PubMed Web of Science ®Google Scholar
• Nixon RM, Thompson SG. Methods for incorporating covariate adjustment, subgroup analysis and between-centre differences into cost–effectiveness evaluations. Health Econ.14, 1217–1229 (2005).
   PubMed Web of Science ®Google Scholar
• O’Hagan A, Stevens J. Assessing and comparing costs: how robust are the bootstrap and method based on asymptotic normality? Health Econ.12, 33–49 (2003).
   PubMed Web of Science ®Google Scholar
• Briggs AH, Gray AM. The distribution of health care costs and their statistical analysis for economic evaluation. J. Health Serv. Res. Policy3, 233–345 (1998).
   PubMedGoogle Scholar
• Thompson SG, Barber JA. How should cost data in pragmatic randomised trials be analysed? Br. Med. J.320, 1197–1200 (2000).
   PubMed Web of Science ®Google Scholar
• Nixon RM, Thompson SG. Parametric modeling of cost data in medical studies. Stat. Med.23, 1311–1331 (2004).
   PubMed Web of Science ®Google Scholar
• Briggs A, Nixon R, Dixon S, Thompson S. Parametric modeling of cost data: some simulation evidence. Health Econ.14, 421–428 (2005).
   PubMed Web of Science ®Google Scholar
• Manning WG, Mullahy J. Estimating log models: to transform or not to transform? Health Econ.20, 461–494 (2001).
   Web of Science ®Google Scholar
• Lumley T, Diehr P, Emerson S, Chen L. The importance of the normality assumption in large public health data sets, Annu Rev Public Health.23, 151–169 (2002).
   PubMed Web of Science ®Google Scholar
• Chaudhary MA, Stearns SC. Confidence intervals for cost–effectiveness ratios: an example from a randomized trial. Stat. Med.15, 1447–1458 (1996).
   PubMed Web of Science ®Google Scholar
• Cochran WG. Sampling Techniques. Wiley & Sons, NY, USA (1997).
   Google Scholar
• Willan AR, O’Brien BJ. Confidence intervals for cost–effectiveness ratios: an application of Fieller’s theorem. Health Econ.5, 297–305 (1996).
   PubMed Web of Science ®Google Scholar
• O’Hagan A, Stevens JW. A framework for cost–effectiveness analysis from clinical trial data. Health Econ.10, 310–315 (2001).
   Google Scholar
• Fenwick E, O’Brien BJ, Briggs AH. Cost-effectiveness acceptability curves – facts, fallacies and frequently asked questions, Health Econ.13, 405–415 (2004).
   PubMed Web of Science ®Google Scholar
• O’Brien BJ, Gertsen K, Willan AR, Faulkner L. Is there a kink in consumers’ threshold value for cost–effectiveness in health care? Health Econ.11, 175–180 (2002).
   PubMed Web of Science ®Google Scholar
• Willan AR, O’Brien BJ, Leyva RA. Cost-effectiveness analysis when the WTA is greater than the WTP. Stat. Med.20, 3251–3259 (2001).
   PubMed Web of Science ®Google Scholar
• Willan AR, Briggs AH, Hoch JS. Regression methods for covariate adjustment and subgroup analysis for non-censored cost–effectiveness data. Health Econ.13, 461–475 (2004).
   PubMed Web of Science ®Google Scholar
• Willan AR, Briggs AH. The Statistical Analysis of Cost-effectiveness Data. Wiley & Sons, London, UK (2006).
   Google Scholar
• Thompson SG, Warn DE, Turner RM. Bayesian methods for analysis of binary outcome data in cluster randomized trials on the absolute risk scale. Stat. Med.23, 389–410 (2004).
   Google Scholar
• Willan AR, Chen EB, Cook RJ, Lin DY. Incremental net benefit in randomized clinical trials with qualify-adjusted survival. Stat. Med.22, 353–362 (2003).
   Google Scholar
• Lin DY, Feuer EJ, Etzioni R, Wax Y. Estimating medical costs from incomplete follow-up data. Biometrics53, 419–434 (1997).
   PubMed Web of Science ®Google Scholar
• Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Stat. Med.20, 1563–1574 (2001).
   PubMed Web of Science ®Google Scholar
• Bang H, Tsiatis AA. Estimating medical costs with censored data. Biometrika87, 329–343 (2000).
   Web of Science ®Google Scholar
• Lin DY. Linear regression analysis of censored medical costs. Biostatistics1, 35–47 (2000).
   PubMedGoogle Scholar
• Zhao H, Tian L. On estimating medical cost and incremental cost–effectiveness ratios with censored data. Biometrics57, 1002–1008 (2001).
   PubMed Web of Science ®Google Scholar
• Willan AR, Lin DY, Manca A. Regression methods for cost–effectiveness analysis with censored data. Stat. Med.24, 131–145 (2005).
   Google Scholar
• Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Chapman & Hall, NY, USA (1993).
   Google Scholar
• Briggs AH, Wonderling DE, Mooney CZ. Pulling cost–effectiveness analysis up by its bootstraps; a non-parametric approach to confidence interval estimation. Health Econ.6, 327–340 (1997).
   PubMed Web of Science ®Google Scholar
• Willan AR, Pinto EM. The expected value of information and optimal clinical trial design. Stat. Med.24, 1791–1806 (2005); Correction Stat. Med.25, 720 (2006).
   PubMed Web of Science ®Google Scholar